Press Releases Archives - Iaso Therapeutics

Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

jeff@orbit.digital2023-01-25T11:03:18-05:00

Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.

Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financingjeff@orbit.digital2023-01-25T11:03:18-05:00

Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research

jeff@orbit.digital2022-03-14T11:27:00-04:00

The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the [...]

Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Researchjeff@orbit.digital2022-03-14T11:27:00-04:00

Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseases

jeff@orbit.digital2022-02-11T13:57:41-05:00

Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) [...]

Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseasesjeff@orbit.digital2022-02-11T13:57:41-05:00

Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fund

jeff@orbit.digital2022-03-14T11:28:08-04:00

East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in [...]

Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fundjeff@orbit.digital2022-03-14T11:28:08-04:00

Press Releases

Iaso Therapeutics Announces First Close in $1.25M Equity Series Seed Preferred Financing

Iaso Therapeutics Receives Grant from the National Science Foundation for Next-Generation Vaccine Research

Iaso Therapeutics Awarded Competitive Grant from the National Institute of Allergy and Infectious Diseases

Iaso Therapeutics secures investment from Michigan State University’s Student Venture Capital Fund

Iaso Therapeutics, Inc.